N‐glycan based models improve diagnostic efficacies in hepatitis B virus‐related hepatocellular carcinoma

The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to constr...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 127; no. 1; pp. 148 - 159
Main Authors Fang, Meng, Zhao, Yun‐Peng, Zhou, Fei‐Guo, Lu, Lun‐Gen, Qi, Peng, Wang, Hao, Zhou, Kun, Sun, Shu‐Han, Chen, Cui‐Ying, Gao, Chun‐Fang
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2010
Wiley-Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N‐glycan based diagnostic model in HCC identification and follow‐up. A total of 393 subjects including HBV‐related HCC, liver fibrosis and healthy controls were recruited. Follow‐up was carried out before and after surgical treatment in HCC. N‐glycome of serum glycoprotein was profiled by DNA sequencer‐assisted fluorophore‐assisted carbohydrate electrophoresis (DSA‐FACE). Multiparameters diagnostic models were constructed based on N‐glycan markers. The result found that 2 N‐glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N‐glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N‐glycan markers (Cscore B) were increased 7–10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N‐glycan markers were found to be changed significantly after surgical resection in HCC follow‐up. We conclude that the branching α (1,3)‐fucosylated triantennary glycan and a biantennary glycan are promising as N‐glycan markers. The diagnostic models based on the N‐glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
AbstractList The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N‐glycan based diagnostic model in HCC identification and follow‐up. A total of 393 subjects including HBV‐related HCC, liver fibrosis and healthy controls were recruited. Follow‐up was carried out before and after surgical treatment in HCC. N‐glycome of serum glycoprotein was profiled by DNA sequencer‐assisted fluorophore‐assisted carbohydrate electrophoresis (DSA‐FACE). Multiparameters diagnostic models were constructed based on N‐glycan markers. The result found that 2 N‐glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N‐glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N‐glycan markers (Cscore B) were increased 7–10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N‐glycan markers were found to be changed significantly after surgical resection in HCC follow‐up. We conclude that the branching α (1,3)‐fucosylated triantennary glycan and a biantennary glycan are promising as N‐glycan markers. The diagnostic models based on the N‐glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N-glycan based diagnostic model in HCC identification and follow-up. A total of 393 subjects including HBV-related HCC, liver fibrosis and healthy controls were recruited. Follow-up was carried out before and after surgical treatment in HCC. N-glycome of serum glycoprotein was profiled by DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). Multiparameters diagnostic models were constructed based on N-glycan markers. The result found that 2 N-glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N-glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N-glycan markers (Cscore B) were increased 7-10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N-glycan markers were found to be changed significantly after surgical resection in HCC follow-up. We conclude that the branching alpha (1,3)-fucosylated triantennary glycan and a biantennary glycan are promising as N-glycan markers. The diagnostic models based on the N-glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N-glycan based diagnostic model in HCC identification and follow-up. A total of 393 subjects including HBV-related HCC, liver fibrosis and healthy controls were recruited. Follow-up was carried out before and after surgical treatment in HCC. N-glycome of serum glycoprotein was profiled by DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). Multiparameters diagnostic models were constructed based on N-glycan markers. The result found that 2 N-glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N-glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N-glycan markers (Cscore B) were increased 7-10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N-glycan markers were found to be changed significantly after surgical resection in HCC follow-up. We conclude that the branching (1,3)-fucosylated triantennary glycan and a biantennary glycan are promising as N-glycan markers. The diagnostic models based on the N-glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N ‐glycan based diagnostic model in HCC identification and follow‐up. A total of 393 subjects including HBV‐related HCC, liver fibrosis and healthy controls were recruited. Follow‐up was carried out before and after surgical treatment in HCC. N ‐glycome of serum glycoprotein was profiled by DNA sequencer‐assisted fluorophore‐assisted carbohydrate electrophoresis (DSA‐FACE). Multiparameters diagnostic models were constructed based on N ‐glycan markers. The result found that 2 N ‐glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N ‐glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N ‐glycan markers (Cscore B) were increased 7–10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N ‐glycan markers were found to be changed significantly after surgical resection in HCC follow‐up. We conclude that the branching α (1,3)‐fucosylated triantennary glycan and a biantennary glycan are promising as N ‐glycan markers. The diagnostic models based on the N ‐glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N-glycan based diagnostic model in HCC identification and follow-up. A total of 393 subjects including HBV-related HCC, liver fibrosis and healthy controls were recruited. Follow-up was carried out before and after surgical treatment in HCC. N-glycome of serum glycoprotein was profiled by DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). Multiparameters diagnostic models were constructed based on N-glycan markers. The result found that 2 N-glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N-glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N-glycan markers (Cscore B) were increased 7-10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N-glycan markers were found to be changed significantly after surgical resection in HCC follow-up. We conclude that the branching alpha (1,3)-fucosylated triantennary glycan and a biantennary glycan are promising as N-glycan markers. The diagnostic models based on the N-glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar chains of glycoprotein synthesized by the liver contribute to the molecular basis of abnormalities in carcinogenesis. This study aims to construct and assess the diagnostic value of N-glycan based diagnostic model in HCC identification and follow-up. A total of 393 subjects including HBV-related HCC, liver fibrosis and healthy controls were recruited. Follow-up was carried out before and after surgical treatment in HCC. N-glycome of serum glycoprotein was profiled by DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). Multiparameters diagnostic models were constructed based on N-glycan markers. The result found that 2 N-glycan structure abundances (NG1A2F, Peak 4; NA3Fb, Peak 9) were useful as N-glycan markers. The diagnostic efficacy of the log ratio [log(p9/4)] was similar to that of AFP in differentiating HCC from fibrosis. The accuracy and sensitivity of the diagnostic model combining AFP and N-glycan markers (Cscore B) were increased 7-10% compared with that of AFP. Log(p9/4) was more efficient in monitoring the progression of HCC with regarding to vascular invasion at improved specificity (16%) and accuracy (8%) compared with that of AFP. The N-glycan markers were found to be changed significantly after surgical resection in HCC follow-up. We conclude that the branching alpha (1,3)-fucosylated triantennary glycan and a biantennary glycan are promising as N-glycan markers. The diagnostic models based on the N-glycan markers and AFP improve the efficacy in HCC diagnosis and progression monitoring.
Author Qi, Peng
Sun, Shu‐Han
Zhou, Kun
Zhao, Yun‐Peng
Zhou, Fei‐Guo
Lu, Lun‐Gen
Fang, Meng
Chen, Cui‐Ying
Gao, Chun‐Fang
Wang, Hao
Author_xml – sequence: 1
  givenname: Meng
  surname: Fang
  fullname: Fang, Meng
– sequence: 2
  givenname: Yun‐Peng
  surname: Zhao
  fullname: Zhao, Yun‐Peng
– sequence: 3
  givenname: Fei‐Guo
  surname: Zhou
  fullname: Zhou, Fei‐Guo
– sequence: 4
  givenname: Lun‐Gen
  surname: Lu
  fullname: Lu, Lun‐Gen
– sequence: 5
  givenname: Peng
  surname: Qi
  fullname: Qi, Peng
– sequence: 6
  givenname: Hao
  surname: Wang
  fullname: Wang, Hao
– sequence: 7
  givenname: Kun
  surname: Zhou
  fullname: Zhou, Kun
– sequence: 8
  givenname: Shu‐Han
  surname: Sun
  fullname: Sun, Shu‐Han
– sequence: 9
  givenname: Cui‐Ying
  surname: Chen
  fullname: Chen, Cui‐Ying
– sequence: 10
  givenname: Chun‐Fang
  surname: Gao
  fullname: Gao, Chun‐Fang
  email: gaocf1115@yahoo.com
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22798560$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19904744$$D View this record in MEDLINE/PubMed
BookMark eNqFkbtuFDEUhi0URDaBghdAbhCimOT4Nh6XZMUlKIIG6pHHYwdHHnuxZ4K24xHyjHkSnOwCEhJQufi_8-n4_EfoIKZoEXpK4IQA0FN_ZU6oAAYP0IqAkg1QIg7QqmbQSMLaQ3RUyhUAIQL4I3RIlAIuOV-h6cPt95vLsDU64kEXO-IpjTYU7KdNTtcWj15fxlRmb7B1zhttvK1pxF_sRs9-9gWf4Wufl1JF2QY9V8d9lowNYQk6Y6Oz8TFN-jF66HQo9sn-PUaf37z-tH7XXHx8e75-ddEY1rXQMNIOynVSGtUaRq0ig2p5C5IaJYRStAOnuBNjJwYtxMCYo1S2XIDk1nLNjtGLnbf-4etiy9xPvtyto6NNS-klF4opCer_JGNUMaa6Sj7bk8sw2bHfZD_pvO1_3rICz_eALkYHl3U0vvzi6oaqEy1U7uWOMzmVkq37rYL-rs--9tnf91nZ0z9Y4-d69hTnrH3418Q3H-z27-r-_P16N_ED9RCxrw
CODEN IJCNAW
CitedBy_id crossref_primary_10_1007_s10238_015_0401_2
crossref_primary_10_1002_elps_201700084
crossref_primary_10_1080_2162402X_2015_1011503
crossref_primary_10_1111_apt_17748
crossref_primary_10_1016_j_cca_2019_04_072
crossref_primary_10_1007_s10719_019_09906_x
crossref_primary_10_3389_fnut_2024_1387461
crossref_primary_10_1021_acs_jproteome_2c00196
crossref_primary_10_1038_srep16007
crossref_primary_10_1002_ijc_33564
crossref_primary_10_1016_j_clinbiochem_2020_12_005
crossref_primary_10_1371_journal_pone_0127022
crossref_primary_10_4236_ojgas_2012_21001
crossref_primary_10_1016_j_dld_2012_12_007
crossref_primary_10_1016_j_jchromb_2019_04_020
crossref_primary_10_3390_app10238401
crossref_primary_10_1038_s41388_023_02702_w
crossref_primary_10_1089_omi_2020_0055
crossref_primary_10_1186_1476_4598_9_215
crossref_primary_10_1371_journal_pone_0077821
crossref_primary_10_1515_cclm_2018_0379
crossref_primary_10_3892_ol_2024_14769
crossref_primary_10_1002_14651858_CD013346_pub2
crossref_primary_10_1515_cclm_2020_1588
crossref_primary_10_1021_ac4006099
crossref_primary_10_1002_elps_202000392
crossref_primary_10_1002_cncr_26342
crossref_primary_10_1016_j_jad_2018_02_082
crossref_primary_10_1371_journal_pone_0094536
crossref_primary_10_1186_s12885_017_3891_3
crossref_primary_10_1021_acs_jproteome_8b00655
crossref_primary_10_1002_jcla_24201
crossref_primary_10_1371_journal_pone_0072704
crossref_primary_10_3892_or_2016_4980
crossref_primary_10_1053_j_gastro_2019_08_060
crossref_primary_10_1002_jcla_23711
crossref_primary_10_1007_s13337_018_0484_y
crossref_primary_10_1186_s12964_024_01569_y
Cites_doi 10.1016/0168-8278(95)80269-X
10.1053/j.gastro.2004.09.024
10.1111/j.1440-1746.2006.04553.x
10.1111/j.1572-0241.2007.01751.x
10.1016/j.jhep.2004.08.008
10.1158/1078-0432.CCR-07-5261
10.1046/j.1440-1746.2000.0150121356.x
10.1158/1078-0432.CCR-06-1025
10.1186/1471-2407-8-200
10.1073/pnas.0408928102
10.1002/pmic.200800163
10.1074/mcp.M600176-MCP200
10.1016/j.jhep.2005.10.019
10.1002/hep.21855
10.1016/j.mad.2008.11.008
10.1038/nprot.2006.60
10.1002/pmic.200800157
10.1016/j.jhep.2005.05.028
10.1053/j.gastro.2008.07.008
10.1373/clinchem.2007.085563
10.1007/978-1-59745-426-1_14
10.1093/glycob/cwj067
10.1002/pmic.200401309
10.1016/S0016-5085(03)00689-9
10.1056/NEJM199306243282502
10.1002/hep.20960
10.1111/j.1440-1711.2005.01351.x
10.1111/j.1572-0241.2006.00467.x
10.1002/pmic.200800046
10.1074/jbc.M605697200
10.1016/j.jhep.2006.12.013
10.1080/00365520410009311
10.1002/hep.20577
10.1016/j.jhep.2006.05.013
10.1016/S0140-6736(00)04258-6
10.1002/cncr.20713
10.1021/pr060664t
10.1021/pr800656e
10.1038/nm1006
ContentType Journal Article
Copyright Copyright © 2009 UICC
2015 INIST-CNRS
Copyright_xml – notice: Copyright © 2009 UICC
– notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U9
H94
DOI 10.1002/ijc.25030
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
DatabaseTitleList
MEDLINE
AIDS and Cancer Research Abstracts
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 159
ExternalDocumentID 19904744
22798560
10_1002_ijc_25030
IJC25030
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Natural Science Foundation of China
  funderid: 30571774; 30971345
– fundername: Science and Technology Commission of Shanghai Municipality
  funderid: 064119522; 09XD1405800The first 3 authors contribute equally to this work
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SUPJJ
TEORI
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
XG1
XPP
XV2
ZZTAW
~IA
~WT
.55
.GJ
3O-
53G
8WZ
A6W
AANHP
AAYXX
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AEYWJ
AGHNM
AGQPQ
AGYGG
AHEFC
AI.
ASPBG
AVWKF
AZFZN
BDRZF
CITATION
EMOBN
FEDTE
GLUZI
HVGLF
M6P
PALCI
SAMSI
VH1
X7M
Y6R
ZGI
ZXP
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U9
H94
ID FETCH-LOGICAL-c3860-316b9f877c96c32e91b9646072c95599280f94f5d85ba55b33f227645074ee4a3
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Thu Jul 10 19:07:49 EDT 2025
Fri Jul 11 03:50:47 EDT 2025
Mon Jul 21 05:57:44 EDT 2025
Mon Jul 21 09:13:03 EDT 2025
Tue Jul 01 02:27:29 EDT 2025
Thu Apr 24 23:07:26 EDT 2025
Wed Jan 22 17:01:54 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Hepatic fibrosis
hepatitis B virus (HBV)
Treatment efficiency
Orthohepadnavirus
Biological marker
Hepatic disease
Hepatocellular carcinoma
hepatocellular carcinoma (HCC)
Malignant tumor
Glycan
Virus
Liver cancer
liver fibrosis
Cancerology
Hepadnaviridae
marker
Digestive diseases
Models
N-glycan
Diagnosis
Hepatitis B virus
Cancer
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3860-316b9f877c96c32e91b9646072c95599280f94f5d85ba55b33f227645074ee4a3
Notes The first 3 authors contribute equally to this work
Tel: 8621 81875131, Fax: +86‐21‐65562400, 86‐21‐81875131
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 19904744
PQID 733293398
PQPubID 23479
PageCount 12
ParticipantIDs proquest_miscellaneous_745939709
proquest_miscellaneous_733293398
pubmed_primary_19904744
pascalfrancis_primary_22798560
crossref_primary_10_1002_ijc_25030
crossref_citationtrail_10_1002_ijc_25030
wiley_primary_10_1002_ijc_25030_IJC25030
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 1 July 2010
PublicationDateYYYYMMDD 2010-07-01
PublicationDate_xml – month: 07
  year: 2010
  text: 1 July 2010
  day: 01
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2010
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Blackwell
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Blackwell
References 2004; 101
2004; 41
2004; 127
1993; 328
2008; 18
2006; 16
2007; 385
2005; 40
2005; 41
2005; 42
2006; 5
2008; 8
2005; 43
2008; 103
2006; 1
2005; 83
2002
2007; 53
2007; 13
2004; 10
2006; 45
2000; 15
2006; 44
2005; 102
2005; 564
1995; 22
2006; 26
2005; 5
2007; 6
2009; 8
2008; 135
2006; 281
2009; 120
2003; 125
2007; 22
2007; 46
2006; 101
2001; 357
2009; 15
e_1_2_6_31_2
e_1_2_6_30_2
Iizuka N (e_1_2_6_33_2) 2006; 26
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_12_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_34_2
e_1_2_6_10_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_39_2
e_1_2_6_17_2
e_1_2_6_38_2
e_1_2_6_14_2
e_1_2_6_37_2
e_1_2_6_15_2
e_1_2_6_36_2
Arnold JN (e_1_2_6_40_2) 2005
e_1_2_6_42_2
e_1_2_6_20_2
e_1_2_6_41_2
e_1_2_6_8_2
Sobin LH (e_1_2_6_26_2) 2002
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_29_2
e_1_2_6_4_2
e_1_2_6_3_2
e_1_2_6_6_2
e_1_2_6_5_2
e_1_2_6_24_2
e_1_2_6_23_2
e_1_2_6_2_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_43_2
e_1_2_6_27_2
e_1_2_6_25_2
References_xml – volume: 5
  start-page: 4581
  year: 2005
  end-page: 8
  article-title: Heat‐shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis
  publication-title: Proteomics
– volume: 127
  start-page: S113
  year: 2004
  end-page: S119
  article-title: Newer markers for hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 101
  start-page: 513
  year: 2006
  end-page: 23
  article-title: Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha‐fetoprotein in diagnosing hepatocellular carcinoma: a systematic review
  publication-title: Am J Gastroenterol
– volume: 53
  start-page: 1254
  year: 2007
  end-page: 63
  article-title: High‐throughput quantitative profiling of serum ‐glycome by MALDI‐TOF mass spectrometry and ‐glycomic fingerprint of liver fibrosis
  publication-title: Clin Chem
– volume: 15
  start-page: 1356
  year: 2000
  end-page: 61
  article-title: Chronic hepatitis B virus infection in Asian countries
  publication-title: J Gastroenterol Hepatol
– volume: 45
  start-page: 529
  year: 2006
  end-page: 38
  article-title: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
  publication-title: J Hepatol
– volume: 18
  start-page: 200
  issue: 8
  year: 2008
  article-title: AFP, PIVKAII, GP3, SCCA‐1 and follisatin as surveillance biomarkers for hepatocellular cancer in non‐alcoholic and alcoholic fatty liver diseases
  publication-title: BMC Cancer
– volume: 281
  start-page: 29797
  year: 2006
  end-page: 806
  article-title: Fucosulation of ‐glycans regulates the secretion of hepatic glycoproteins into bile ducts
  publication-title: J Bio Chem
– volume: 22
  start-page: 112
  year: 1995
  end-page: 14
  article-title: The nomenclature of chronic hepatitis: time for a change
  publication-title: J Hepatol
– volume: 10
  start-page: 429
  year: 2004
  end-page: 34
  article-title: Noninvasive diagnosis of liver cirrhosis using DNA‐sequencer based total serum protein glycomics
  publication-title: Nat Med
– volume: 120
  start-page: 92
  year: 2009
  end-page: 7
  article-title: ‐glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing
  publication-title: Mech Ageing Dev
– volume: 8
  start-page: 463
  year: 2009
  end-page: 70
  article-title: Serum protein ‐glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis
  publication-title: J Proteome Res
– volume: 103
  start-page: 1421
  year: 2008
  end-page: 6
  article-title: Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management
  publication-title: Am J Gastroenterol
– volume: 564
  start-page: 27
  year: 2005
  end-page: 43
– volume: 13
  start-page: 1133
  year: 2007
  end-page: 9
  article-title: Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma
  publication-title: Clin Cancer Res
– volume: 5
  start-page: 1957
  year: 2006
  end-page: 67
  article-title: Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers
  publication-title: Mol Cell Proteomics
– volume: 44
  start-page: 462
  year: 2006
  end-page: 74
  article-title: Performance of serum marker panels for liver fibrosis in chronic hepatitis C
  publication-title: J Hepatol
– volume: 328
  start-page: 1802
  year: 1993
  end-page: 6
  article-title: Early recognition of hepatocellular carcinoma based on altered profiles of alpha‐fetoprotein
  publication-title: N Engl J Med
– volume: 8
  start-page: 3257
  year: 2008
  end-page: 62
  article-title: Fucosylated hatoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures
  publication-title: Proteomics
– volume: 15
  start-page: 1808
  year: 2009
  end-page: 13
  article-title: Detection of hepatocellular carcinoma using glycomics analysis
  publication-title: Clin Cancer Res
– volume: 83
  start-page: 429
  year: 2005
  end-page: 39
  article-title: Altered glycosylation of proteinss produced by malignent cells, and application for the diagnosis and immunotherapy of tumors
  publication-title: Immunol Cell Biol
– volume: 135
  start-page: 1192
  year: 2008
  end-page: 9
  article-title: HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 8
  start-page: 3284
  year: 2008
  end-page: 93
  article-title: Evaluation of the serum N‐linked glycome for the diagnosis of cancer and chronic inflammation
  publication-title: Proteomics
– volume: 1
  start-page: 397
  year: 2006
  end-page: 405
  article-title: Glycome mapping on DNA‐sequencing equipment
  publication-title: Nat Protoc
– volume: 40
  start-page: 68
  year: 2005
  end-page: 75
  article-title: Serum insulin‐like growth factor‐II as a serologic marker of small hepatocellular carcinoma
  publication-title: Scand J Gastroenterol
– volume: 22
  start-page: 1148
  year: 2007
  end-page: 54
  article-title: Rating of CCl(4)‐induced rat liver fibrosis by blood serum glycomics
  publication-title: J Gastroenterol Hepatol
– volume: 8
  start-page: 3210
  year: 2008
  end-page: 20
  article-title: Focused glycomic analysis of the N‐linked glycan biosynthetic pathway in ovarian cancer
  publication-title: Proteomics
– volume: 101
  start-page: 2825
  year: 2004
  end-page: 36
  article-title: Alpha1‐acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis
  publication-title: Cancer
– volume: 125
  start-page: 89
  year: 2003
  end-page: 97
  article-title: Glypican‐3: a novel serum and histochemical marker for hepatocellular carcinoma
  publication-title: Gastroenterology
– volume: 43
  start-page: 1007
  year: 2005
  end-page: 12
  article-title: GP73, a resident Glogi glycoprotein is a novel serum marker for hepatocellular carcinoma
  publication-title: Hepatology
– volume: 357
  start-page: 1069
  year: 2001
  end-page: 75
  article-title: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
  publication-title: Lancet
– year: 2002
– volume: 26
  start-page: 4713
  year: 2006
  end-page: 19
  article-title: Elevated levels of circulating cell‐free DNA in the blood of patients with hepatitis C virus‐associated hepatocellular carcinoma
  publication-title: Anticancer Res
– volume: 6
  start-page: 1822
  year: 2007
  end-page: 32
  article-title: Alterations in the serum glycome due to metastatic prostate cancer
  publication-title: J Proteome Res
– volume: 42
  start-page: 1437
  year: 2005
  end-page: 45
  article-title: Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model
  publication-title: Hepatology
– volume: 41
  start-page: 935
  year: 2004
  end-page: 42
  article-title: Evaluation of a panel of non‐invasive serum markers to differentiate mild from moderate‐to‐advanced liver fibrosis in chronic hepatitis C patients
  publication-title: J Hepatol
– volume: 46
  start-page: 775
  year: 2007
  end-page: 82
  article-title: Prospective comparison of six non‐invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C
  publication-title: J Hepatol
– volume: 385
  start-page: 193
  year: 2007
  end-page: 203
  article-title: Lectin microarrays for glycoprotein analysis
  publication-title: Methods Mol Biol
– volume: 16
  start-page: 281
  year: 2006
  end-page: 93
  article-title: Mass spectrometric approach for screening modifications of total serum ‐glycome in human diseases: application to cirrhosis
  publication-title: Glycobiology
– volume: 102
  start-page: 779
  year: 2005
  end-page: 84
  article-title: Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans
  publication-title: Proc Natl Acad Sci USA
– volume: 41
  start-page: 634
  year: 2005
  end-page: 42
  article-title: SELDI‐TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma
  publication-title: Hepatology
– volume: 46
  start-page: 1426
  year: 2007
  end-page: 35
  article-title: ‐glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus
  publication-title: Hepatology
– ident: e_1_2_6_27_2
  doi: 10.1016/0168-8278(95)80269-X
– ident: e_1_2_6_30_2
  doi: 10.1053/j.gastro.2004.09.024
– ident: e_1_2_6_43_2
  doi: 10.1111/j.1440-1746.2006.04553.x
– ident: e_1_2_6_4_2
  doi: 10.1111/j.1572-0241.2007.01751.x
– ident: e_1_2_6_35_2
  doi: 10.1016/j.jhep.2004.08.008
– ident: e_1_2_6_41_2
  doi: 10.1158/1078-0432.CCR-07-5261
– ident: e_1_2_6_2_2
  doi: 10.1046/j.1440-1746.2000.0150121356.x
– ident: e_1_2_6_7_2
  doi: 10.1158/1078-0432.CCR-06-1025
– ident: e_1_2_6_6_2
  doi: 10.1186/1471-2407-8-200
– ident: e_1_2_6_37_2
  doi: 10.1073/pnas.0408928102
– ident: e_1_2_6_17_2
  doi: 10.1002/pmic.200800163
– ident: e_1_2_6_38_2
  doi: 10.1074/mcp.M600176-MCP200
– ident: e_1_2_6_12_2
  doi: 10.1016/j.jhep.2005.10.019
– ident: e_1_2_6_25_2
  doi: 10.1002/hep.21855
– ident: e_1_2_6_39_2
  doi: 10.1016/j.mad.2008.11.008
– ident: e_1_2_6_22_2
  doi: 10.1038/nprot.2006.60
– ident: e_1_2_6_18_2
  doi: 10.1002/pmic.200800157
– ident: e_1_2_6_31_2
  doi: 10.1016/j.jhep.2005.05.028
– ident: e_1_2_6_5_2
  doi: 10.1053/j.gastro.2008.07.008
– ident: e_1_2_6_15_2
  doi: 10.1373/clinchem.2007.085563
– ident: e_1_2_6_24_2
  doi: 10.1007/978-1-59745-426-1_14
– ident: e_1_2_6_23_2
  doi: 10.1093/glycob/cwj067
– volume-title: TNM classification of malignant tumors
  year: 2002
  ident: e_1_2_6_26_2
– ident: e_1_2_6_8_2
  doi: 10.1002/pmic.200401309
– ident: e_1_2_6_28_2
  doi: 10.1016/S0016-5085(03)00689-9
– ident: e_1_2_6_36_2
  doi: 10.1056/NEJM199306243282502
– ident: e_1_2_6_10_2
  doi: 10.1002/hep.20960
– ident: e_1_2_6_16_2
  doi: 10.1111/j.1440-1711.2005.01351.x
– ident: e_1_2_6_29_2
  doi: 10.1111/j.1572-0241.2006.00467.x
– start-page: 27
  year: 2005
  ident: e_1_2_6_40_2
– ident: e_1_2_6_19_2
  doi: 10.1002/pmic.200800046
– ident: e_1_2_6_14_2
  doi: 10.1074/jbc.M605697200
– ident: e_1_2_6_11_2
  doi: 10.1016/j.jhep.2006.12.013
– ident: e_1_2_6_32_2
  doi: 10.1080/00365520410009311
– volume: 26
  start-page: 4713
  year: 2006
  ident: e_1_2_6_33_2
  article-title: Elevated levels of circulating cell‐free DNA in the blood of patients with hepatitis C virus‐associated hepatocellular carcinoma
  publication-title: Anticancer Res
– ident: e_1_2_6_9_2
  doi: 10.1002/hep.20577
– ident: e_1_2_6_3_2
  doi: 10.1016/j.jhep.2006.05.013
– ident: e_1_2_6_34_2
  doi: 10.1016/S0140-6736(00)04258-6
– ident: e_1_2_6_13_2
  doi: 10.1002/cncr.20713
– ident: e_1_2_6_20_2
  doi: 10.1021/pr060664t
– ident: e_1_2_6_42_2
  doi: 10.1021/pr800656e
– ident: e_1_2_6_21_2
  doi: 10.1038/nm1006
SSID ssj0011504
Score 2.2076638
Snippet The early diagnosis of hepatocellular carcinoma (HCC) is of great clinical desirable due to lack of specific and sensitive markers. Alterations in the sugar...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 148
SubjectTerms Adult
Biological and medical sciences
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - virology
Female
Gastroenterology. Liver. Pancreas. Abdomen
hepatitis B virus (HBV)
Hepatitis B virus - pathogenicity
hepatocellular carcinoma (HCC)
Humans
Immunoglobulin G - blood
liver fibrosis
Liver Neoplasms - diagnosis
Liver Neoplasms - virology
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
marker
Medical sciences
Models, Theoretical
N‐glycan
Polysaccharides - analysis
Reproducibility of Results
Sensitivity and Specificity
Tumors
Title N‐glycan based models improve diagnostic efficacies in hepatitis B virus‐related hepatocellular carcinoma
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.25030
https://www.ncbi.nlm.nih.gov/pubmed/19904744
https://www.proquest.com/docview/733293398
https://www.proquest.com/docview/745939709
Volume 127
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxUxFA6lCxHE9-P6KEFcuJnbad7BlRZLLbQLsdCFMCSZRK-2c0vn3kJd-RP8jf4Sz8k8ypUq4m4gJyGTnJzzJTn5DiEvPCu1rx0rYvKmEKx2hfMOjKGMKYQtl1zAh8L7B2r3UOwdyaM18mp4C9PxQ4wHbrgysr3GBe58u3lJGjr7Eqbgvznu1zFWCwHR-5E6CoFOz8BcFrARUwOrUMk2x5orvujGqWthWFKXz-IqwLmKX7MD2rlFPg5d7-JOvk6XCz8N335jdfzPf7tNbvbAlL7uNOkOWYvNXXJtv796v0dODn5-__Hp-AKmgqLrq2lOotPSWT6WiLTugvagOo3IS-HAakBpQz9HjNpezFr6hp7PzpYtNJSf0EAbuWyOtwcYDksDZjZq5ifuPjncefthe7foczUUgRuFplx5m4zWwarAWbRb3iqhSs0CctxZZspkRZK1kd5J6TlPjGklAI6KGIXjD8h6M2_iI0JBTVSSQWvjglBRe2OTVtI6LnyonZmQl8OsVaEnMsd8GsdVR8HMKhi-Kg_fhDwfRU879o6rhDZWpn6URHJFA4hwQuigCxUsPhwT18T5sq005wCXuDV_ERHSAuYr7YQ87NTosieABIQWAn4oK8Ofu1i929vOH4__XfQJud5FOmBo8VOyvjhbxmcAoBZ-I6-UX0QAGZM
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFA6lggri_bJeahAffJntNMnkAn3RYtnW7j5IC32RIckkdms7Wzq7gj75E_yN_SWeJDNTVqqIbwM5CZnk5Jwvycl3EHptSC5MpUnmvJEZI5XOtNFgDAvnrd3QXtvwUHg84aMDtntYHK6gze4tTOKH6A_cwsqI9jos8HAgvX7JGjo9tkNw4BQ27NdCRu-4ofrYk0cFqNNyMOcZbMV4xyuUk_W-6pI3unWmGxgYnzJaXAU5lxFsdEHbd9CnrvMp8uTLcDE3Q_v9N17H__27u-h2i03x26RM99CKq--j6-P29v0BOp1c_Pj5-eQbzAYO3q_CMY9Og6fxZMLhKsXtQXXsAjWFBsMBpTU-ciFwez5t8Dv8dXq-aKCh-IoG2ohls3CBECJisQ3JjerZqX6IDrbf72-NsjZdQ2ap5MGac6O8FMIqbilxasMoznguiA00d4rI3Cvmi0oWRheFodQTIjgDRMqcY5o-Qqv1rHZPEAZN4b6wQkhtGXfCSOUFL5SmzNhKywF6001baVsu85BS46RMLMykhOEr4_AN0Kte9CwReFwltLY0971k4FeUAAoHCHfKUML6C2OiazdbNKWgFBATVfIvIqxQAPtyNUCPkx5d9gTAABOMwQ9FbfhzF8ud3a348fTfRV-iG6P98V65tzP58AzdTIEPIdL4OVqdny_cC8BTc7MWl80vvk4drg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFA6lQhGk3tv1UoP44Mtsp0kmF3zS1qWtdhGx0AdhSDKJrrazS2dX0Cd_gr_RX-JJMjNlpYr4NpCTkEnOOfmSnHwHoSeG5MJUmmTOG5kxUulMGw3OsHDe2h3ttQ0PhY_GfP-YHZ4UJyvoWfcWJvFD9AduwTKivw4GPqv89gVp6OSTHcL6TWG_foXxXAaV3nvbc0cFpNNSMOcZ7MR4RyuUk-2-6tJidG2mGxgXnxJaXIY4lwFsXIFG19H7ru8p8OTzcDE3Q_vtN1rH__y5G2i9Rab4eVKlm2jF1bfQ2lF7934bnY1_fv_x4fQrzAUOa1-FYxadBk_iuYTDVYrag-rYBWIKDW4DSmv80YWw7fmkwS_wl8n5ooGG4hsaaCOWTcP1QYiHxTakNqqnZ_oOOh69fLe7n7XJGjJLJQ--nBvlpRBWcUuJUztGcZgXQWwguVNE5l4xX1SyMLooDKWeEMEZ4FHmHNP0Llqtp7XbRBj0hPvCCiG1ZdwJI5UXvFCaMmMrLQfoaTdrpW2ZzENCjdMycTCTEoavjMM3QI970Vmi77hMaGtp6nvJwK4oARIOEO50oQTrC2OiazddNKWgFPASVfIvIqxQAPpyNUAbSY0uegJQgAnG4IeiMvy5i-XB4W78uPfvoo_Q2pu9Ufn6YPzqPrqaoh5CmPEDtDo_X7iHAKbmZisazS92VBxm
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=N-glycan+based+models+improve+diagnostic+efficacies+in+hepatitis+B+virus-related+hepatocellular+carcinoma&rft.jtitle=International+journal+of+cancer&rft.au=Fang%2C+Meng&rft.au=Zhao%2C+Yun-Peng&rft.au=Zhou%2C+Fei-Guo&rft.au=Lu%2C+Lun-Gen&rft.date=2010-07-01&rft.issn=0020-7136&rft.volume=127&rft.issue=1&rft.spage=148&rft.epage=159&rft_id=info:doi/10.1002%2Fijc.25030&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon